[HTML][HTML] ROS and the DNA damage response in cancer

US Srinivas, BWQ Tan, BA Vellayappan… - Redox biology, 2019 - Elsevier
Reactive oxygen species (ROS) are a group of short-lived, highly reactive, oxygen-
containing molecules that can induce DNA damage and affect the DNA damage response …

Replication stress and cancer

H Gaillard, T García-Muse, A Aguilera - Nature Reviews Cancer, 2015 - nature.com
Genome instability is a hallmark of cancer, and DNA replication is the most vulnerable
cellular process that can lead to it. Any condition leading to high levels of DNA damage will …

Triple negative breast cancer: a review of present and future diagnostic modalities

SA Dass, KL Tan, R Selva Rajan, NF Mokhtar… - Medicina, 2021 - mdpi.com
Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal …

Molecular pathways: targeting ATR in cancer therapy

LM Karnitz, L Zou - Clinical cancer research, 2015 - AACR
The human ATR gene encodes a kinase that is activated by DNA damage and replication
stress as a central transducer of a checkpoint signaling pathway. Once activated, ATR …

Hydrogen sulfide biology and its role in cancer

S Khattak, MA Rauf, NH Khan, QQ Zhang, HJ Chen… - Molecules, 2022 - mdpi.com
Hydrogen sulfide (H2S) is an endogenous biologically active gas produced in mammalian
tissues. It plays a very critical role in many pathophysiological processes in the body. It can …

Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis

AB Bukhari, CW Lewis, JJ Pearce… - The Journal of …, 2019 - Am Soc Clin Investig
We used the cancer-intrinsic property of oncogene-induced DNA damage as the base for a
conditional synthetic lethality approach. To target mechanisms important for cancer cell …

Targeting the checkpoint to kill cancer cells

J Benada, L Macurek - Biomolecules, 2015 - mdpi.com
Cancer treatments such as radiotherapy and most of the chemotherapies act by damaging
DNA of cancer cells. Upon DNA damage, cells stop proliferation at cell cycle checkpoints …

Clinical candidates targeting the ATR–CHK1–WEE1 axis in cancer

L Gorecki, M Andrs, J Korabecny - Cancers, 2021 - mdpi.com
Simple Summary Selective killing of cancer cells is privileged mainstream in cancer
treatment and targeted therapy represents the new tool with a potential to pursue this aim. It …

Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy

L Gorecki, M Andrs, M Rezacova… - Pharmacology & …, 2020 - Elsevier
Chemoresistance, radioresistance, and the challenge of achieving complete resection are
major driving forces in the search for more robust and targeted anticancer therapies …

Targeting the DNA damage response for cancer therapy by inhibiting the kinase Wee1

AB Bukhari, GK Chan, AM Gamper - Frontiers in Oncology, 2022 - frontiersin.org
Cancer cells typically heavily rely on the G2/M checkpoint to survive endogenous and
exogenous DNA damage, such as genotoxic stress due to genome instability or radiation …